Skip to content

Development and Evaluation of an Electronic Health Record-based Medication Complete Communication (EMC2) Strategy

Development and Evaluation of an Electronic Health Record-based Medication Complete Communication (EMC2) Strategy (Phase 2)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03652272
Enrollment
301
Registered
2018-08-29
Start date
2019-02-08
Completion date
2021-09-27
Last updated
2025-03-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medication Adherence

Keywords

medication safety, adherence, electronic health record

Brief summary

There is a well-documented need for effective interventions that can help patients understand and safely adhere to prescribed medications, particularly those with greater potential for harm if not taken correctly. The investigators will leverage health and consumer technologies with their EHR-based Medication Complete Communication (EMC2) Strategy to: 1) inform patients about medication risks and safe use, 2) promote provider education and counseling about prescribed drugs and 3) monitor patient adherence outside of visits. The EMC2 Strategy could be feasible, sustainable, and readily available to ambulatory care practices.

Detailed description

This is a 2-arm, multi-site, physician-randomized pragmatic trial to evaluate the impact and scalability of the EMC2 strategy to promote safe medication use and adherence. Treatment Arms and Duration: Usual Care. Usual care includes 1) variable provider counseling with limited or variable EHR notifications or counseling support; 2) no distribution of print medication information materials, including FDA Medication Guides in clinics and variable distribution in pharmacies; and 3) limited or no active surveillance of medication use post-visits. Intervention: EMC2 Strategy. In brief, there are several components to this strategy that will be embedded into the workflow via EHR/patient portal platforms, mostly automating their implementation. Following patient movement through a provider visit, the following activities will occur for a select list of pre-specified medications: 1. Physician Medication Alert: If a prescribing physician attempts to place a new order or change to an existing study medication prescription, an EHR-generated alert will notify the provider that the medication requires patient counseling. Physicians can opt to ignore this alert. 2. Provider Counseling Support: Content from the 1-page, Med Guide Summary will appear on the screen, if selected by the provider, to orient and inform provider-patient discussion. 3. Automated Delivery of Med Guide + Summary: When patients leave an encounter, the medication order in Epic will automatically cue printing of both the 1-page, health literate Med Guide Summary for study medications and a full Med Guide, if applicable (latter is required by FDA for certain medications only, the former designed to enhance comprehension). 4. Follow-Up Portal Questionnaire: Within 1 week post-visit, patients will receive an automated email prompting them to log on to the patient portal. Patients' will be asked to fill out a short set of questions related to medication adherence, and other medication-related concerns (i.e. cost, side effects). If patients have not completed the questionnaire within 2 days, another email reminder will be sent. The information submitted back by the patient will be stored in the EHR. A second questionnaire will be sent 1 month later. The addition of the patient portal will provide opportunities to have ongoing communications with their clinic, access to regimen-specific medication information, and to provide a feedback loop informing healthcare providers of safety and adherence-related behaviors and concerns. 5. EHR Inbox Message to Clinic: The results of the patient portal questionnaire will be sent back to the EHR, populating an inbox message notifying the nurse/clinic staff and/or physician if a patient has a medication risk alert, detailing the nature of the issue (i.e. education needed, adherence problem, side effect concerns, etc.). The system will be flexible and allow the clinic to specify actions to be taken according to their workflow preferences; the default plan is that patient contact will be undertaken by nurses/clinic staff involved with care management. 6. Clinic Counseling: If a problem/concern is flagged during the review of the portal questionnaire, there will be an expectation for a clinic staff member to respond to the concern by calling the patient. A general orientation to staff at the clinic will provide guidance on how to perform brief counseling based on each specific clinic protocol. Number of Patients: While the expected sample size for this pragmatic study is 300, the investigators will recruit 330 patients (n=165 per site, the investigators anticipate 90% retention among the recruited sample by 3 months (n=297). The investigators therefore will over sample to accommodate some attrition.

Interventions

BEHAVIORALEMC2

1. Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks 2. Patients will receive a Medication Guide + Summary with their After Visit Summary 3. Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study) 4. Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols.

Sponsors

Eli Lilly and Company
CollaboratorINDUSTRY
Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

2-arm, multi-site, physician-randomized pragmatic trial to evaluate the impact and scalability of the Phase I EMC2 strategy to promote safe medication use and adherence.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patient is age 18 and older * Patient is English speaking * Patient is primarily responsible for administering their own medication * Patient must have received a new or changed prescription for a product(s), identified by Eli Lilly and the study team, within 7 days of recruitment * Patient must have access to the internet * Patient must have a patient portal account

Exclusion criteria

* Severe, uncorrectable vision * Severe hearing impairments * Severe cognitive impairment * No access to the internet or patient portal account Providers must meet the following eligibility criteria: • Resident, Attending Physician or Mid-level provider (NP, PA) working in the NMHC Endocrinology clinic or other study sites during study dates. \*Adults unable to consent, individuals under the age of 18, and prisoners will be excluded from this research.

Design outcomes

Primary

MeasureTime frameDescription
Medication Specific KnowledgeBaselinePatients are asked about their medication's 1) indication, 2) risks or warnings (knowledge of risk/warnings, correct or incorrect per item) and 3) side effects (knowledge of at least two side effects, correct or incorrect per item). Correct answers were graded blindly by 2 reviewers and any discordance was resolved by a third pharmacist. Total scores ranged from 0-100, with a higher value associated with a better outcome, that reflects the percent correct of possible points.

Secondary

MeasureTime frameDescription
Medication Adherence- Ask 12Baseline-3 MonthsThe ASK-12 survey covers three adherence domains: inconvenience/forgetfulness, treatment beliefs and behavior. Scores range from 12-60, with higher scores translating to greater barriers to adherence.
Medication Adherence - Proper UseBaseline- 3 MonthsPatients will be asked the last day they took their medication and how. A patient's proper timing (last day and # of times per day), dosing (number of pills per dose), and spacing between doses (for BID, TID medications only) will be coded as correct or incorrect. Patients will be classified as having properly used their medication if they correctly reported all components.

Countries

United States

Participant flow

Participants by arm

ArmCount
EMC2
Following patient movement through a provider visit, the following activities will occur for a select list of pre-specified medications: 1. Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks 2. Patients will receive a Medication Guide + Summary with their After Visit Summary 3. Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study) 4. Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols. EMC2: 1) Prescribers will receive a 'Best Practices Alert' which recommends patient counseling on medication use and provides an overview of key medication risks 2) Patients will receive a Medication Guide + Summary with their After Visit Summary 3) Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study) 4) Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols.
143
Usual Care
Usual care includes 1) variable provider counseling with limited or variable EHR notifications or counseling support; 2) no distribution of print medication information materials, including FDA Medication Guides in clinics and variable distribution in pharmacies; and 3) limited or no active surveillance of medication use post-visits.
158
Total301

Withdrawals & dropouts

PeriodReasonFG000FG001
3 MonthLost to Follow-up1614
3 MonthWithdrawal by Subject11

Baseline characteristics

CharacteristicEMC2Usual CareTotal
Age, Continuous52.58 years
STANDARD_DEVIATION 13.99
53.61 years
STANDARD_DEVIATION 14.88
53.12 years
STANDARD_DEVIATION 14.44
Education
College Graduate
73 Participants94 Participants167 Participants
Education
High School Graduate
59 Participants59 Participants118 Participants
Education
Less than High School
10 Participants4 Participants14 Participants
Race/Ethnicity, Customized
Hispanic
20 Participants21 Participants41 Participants
Race/Ethnicity, Customized
Non-Hispanic Black
60 Participants41 Participants101 Participants
Race/Ethnicity, Customized
Non-Hispanic Others/Multiracial
11 Participants13 Participants24 Participants
Race/Ethnicity, Customized
Non-Hispanic White
50 Participants82 Participants132 Participants
Sex: Female, Male
Female
82 Participants95 Participants177 Participants
Sex: Female, Male
Male
61 Participants62 Participants123 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1430 / 158
other
Total, other adverse events
4 / 1436 / 158
serious
Total, serious adverse events
0 / 1430 / 158

Outcome results

Primary

Medication Specific Knowledge

Patients are asked about their medication's 1) indication, 2) risks or warnings (knowledge of risk/warnings, correct or incorrect per item) and 3) side effects (knowledge of at least two side effects, correct or incorrect per item). Correct answers were graded blindly by 2 reviewers and any discordance was resolved by a third pharmacist. Total scores ranged from 0-100, with a higher value associated with a better outcome, that reflects the percent correct of possible points.

Time frame: Baseline

Population: This trial was conducted at Northwestern Endocrinology and ACCESS Community Health Network. Due to the Covid-19 pandemic and its impact on recruitment (loss of providers, low patient volume, low prescription volume) at ACCESS performance sites, recruitment was halted in March 2021. The effectiveness of the intervention will be only tested on the Northwestern participants due to statistical power. 2 patients from the intervention group were excluded due to missing outcomes data at follow-up.

ArmMeasureValue (LEAST_SQUARES_MEAN)
EMC2Medication Specific Knowledge63.82 score (0-100)
Usual CareMedication Specific Knowledge62.80 score (0-100)
Secondary

Medication Adherence- Ask 12

The ASK-12 survey covers three adherence domains: inconvenience/forgetfulness, treatment beliefs and behavior. Scores range from 12-60, with higher scores translating to greater barriers to adherence.

Time frame: Baseline-3 Months

ArmMeasureValue (LEAST_SQUARES_MEAN)
EMC2Medication Adherence- Ask 1222.33 units on a scale
Usual CareMedication Adherence- Ask 1221.56 units on a scale
Secondary

Medication Adherence - Proper Use

Patients will be asked the last day they took their medication and how. A patient's proper timing (last day and # of times per day), dosing (number of pills per dose), and spacing between doses (for BID, TID medications only) will be coded as correct or incorrect. Patients will be classified as having properly used their medication if they correctly reported all components.

Time frame: Baseline- 3 Months

Population: The EMC2 Phase 2 Trial is conducted at Northwestern Endocrinology and ACCESS Community Health Network. Due to the Ccovid-19 pandemic and its impact on recruitment (loss of providers, low patient volume, low prescription volume) at ACCESS performance sites, recruitment was halted in March 2021. The Effectiveness of the intervention will be only tested on the Northwestern participants due to statistical power.

ArmMeasureValue (LEAST_SQUARES_MEAN)
EMC2Medication Adherence - Proper Use0.78 Probability of Proper Use (Yes)
Usual CareMedication Adherence - Proper Use0.62 Probability of Proper Use (Yes)

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026